ALFA Filings
Every announcement, straight from the exchange
Every Eris Lifesciences earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
8 announcements with these filters
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q1 FY27 showed 13% revenue growth, but shifting product mix toward lower-margin biologics and insulin is compressing gross margins. Management remains optimistic about GLP-1 uptake despite slow initial patient adoption.
Eris reports steady 14% domestic growth but faces a gross margin contraction due to a higher mix of lower-margin biologics and insulin products.
Eris reports 13% YoY revenue growth in Q1 FY27, reaching ₹873 Cr, driven by a 14% increase in Domestic Branded Formulations (DBF) and strategic expansion into biologics and insulins.
Eris reports FY26 revenue of INR 3,129 cr with 36% EBITDA margin. Strategy focused on high-value therapies (80% revenue) and aggressive M&A integration.
Eris Lifesciences Q3 FY26 results show a 10% YoY revenue increase, led by aggressive insulin market share gains, while discontinuing non-core brands to optimize margins.
Eris delivered record Q3 revenue but faces near-term margin pressure from new launch investments and non-core portfolio pruning.
Eris reports FY26 revenue of ₹3,129 cr (up 8.1% yoy) with 35.8% EBITDA margin. Strategy focuses on Gx Semaglutide leadership and scaling international CDMO business.